Researchers at Johns Hopkins and their collaborators conducted an open-label phase I clinical trial of a new treatment, in which a viral vector expressing the gene for sFLT01, a protein that ...

Age-related macular degeneration is the leading cause of vision loss in those who are age 50 or older. In fact, almost 20 million people in the U.S. have some type of age-related macular ...

Aug. 24, 2022 — Researchers have developed a new gene therapy approach that shows promise for treating the dry form of Age Related Macular Degeneration (AMD) -- a progressive eye disease that ...

DelveInsight's 'Dry Age-Related Macular Degeneration Pipeline Insight 2025' report provides comprehensive global coverage of ...

Last year, it claimed a $370 million licensing deal with AbbVie for an AAV8 gene therapy candidate RGX-314 for wet age-related macular degeneration (AMD).

The genetic medicines biotech is discarding a choroideremia program assessing a gene therapy dubbed 4D ... 3 clinical trials in wet age-related macular degeneration, or wet AMD, for 4D-150.

The global macular degeneration treatment market size was valued at USD 10.06 billion in 2024 and it is projected to reach ...

The investment gives Sanofi rights of first refusal on GT005, Gyrocope's lead gene therapy for geographic atrophy (GA) secondary to age-related macular degeneration (AMD), a major cause of ...

Previous research has shown that voretigene neparvovec administered subretinally early in childhood for RPE65-mediated ...

Dry Age-Related Macular Degeneration Market The healthcare landscape in 2025 is poised for a transformative shift, driven by innovation and ...

Adverum Biotechnologies (NASDAQ: ADVM) is a clinical-stage company that aims to establish gene therapy as a new standard of care for highly prevalent ocular diseases with the aspiration of developing ...

Introduction The eye's macula is impacted by macular degeneration, a neurodegenerative condition. Macular degeneration will cause loss of centr ...